Effect of Modified ERAS Protocol on Clinical Outcomes in Pediatric Patients With Appendectomy

September 30, 2025 updated by: Buket MERAL, Karadeniz Technical University

Effect of Enhanced Recovery After Surgery Protocol Based Care on Patient Outcomes in Children With Appendicitis: a Randomized Controlled Trial

Acute appendicitis is the most common abdominal emergency with more than 15 million cases reported worldwide. Although appendectomy is considered a safe surgical procedure, the incidence of complications is up to 10%. The Enhanced Recovery After Surgery (ERAS) has developed guidelines to improve postoperative patient outcomes. The protocol, which consists of more than 20 interventions in the preoperative, intraoperative and postoperative periods, shows that early discharge can be possible with multidisciplinary care given to surgical patients without risking patient safety.

Study Overview

Detailed Description

Appendicitis is a common clinical condition and often requires emergency treatment. Although appendectomy is a safe surgical procedure, there is a risk of complications. Pain is common, especially in the postoperative period, and the lack of care management leads to delayed mobilization and oral intake, delayed recovery and prolonged length of hospital stay. However, pain, nausea-vomiting, thirst, fear and stress could be managed with perioperative care. In addition, it is reported that the care provided based on the ERAS protocol shortens the length of hospital stay. In this respect, the aim of this study was to investigate the effect of ERAS protocol-based care on the length of hospital stay of children who were planned to undergo appendectomy. Postoperative pain level, stress and fear level, time to first mobilization, flatulence, defecation and oral intake, nausea, thirst were the secondary outcomes of this study.

Study Type

Interventional

Enrollment (Actual)

82

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Trabzon
      • Trabzon, Trabzon, Turkey (Türkiye), 61080
        • Karadeniz Technical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age ≥6 years and ≤17 years, girls or boys
  • Underwent appendectomy
  • Written informed consent or requirements of local/national ethical committee

Exclusion Criteria:

  • ASA (American Society of Anesthesiologists, ASA) score of ≥ 3
  • Any comorbidity/contraindication that may prevent mobilization and oral feeding

The withdrawal criteria:

  • During the surgery, the surgeon classified appendicitis as grade 0 (no appendicitis) or grade IIIB and above,
  • during the postoperative period need for intensive care hospitalization patients in the control or the mERAS protocol group were staying in the same room,
  • contraindications to the application of any intervention in the intervention group and/or the primary physician not approving the application of the intervention,
  • the compliance rate of the interventions determined in the modified ERAS protocol being below 80%,
  • the development of any other comorbidity (urinary calculi, intussusception, etc.),
  • the change in the type of surgery during the operation, conversion from laparoscopic to open appendectomy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Standart Care Group
Patients in this group will receive standard care according to the practices of the clinic where the study will be conducted.
Experimental: mERAS Group
  • Education and counselling of patients and their parents
  • Avoiding the use of nasogastric catheters, drains and urinary catheters or/and removing them as early as possible
  • Stimulation of intestinal motility in the postoperative period
  • Initiation of oral intake in the early postoperative period
  • Early removal of the patient by reducing postoperative IV fluid infusion
  • Initiation of early mobilization of the patient in the postoperative period
  • Providing pain management with opioid-limiting pharmacologic and non-pharmacological interventions
  • Non-pharmacological interventions in management nausea and vomiting
  • Management of thirsty through non-pharmacological interventions
  • Management of fear and anxiety through non-pharmacological interventions
Education and counselling of patients and their parents
Avoiding the use of nasogastric catheters, drains and urinary catheters or/and removing them as early as possible
Stimulation of intestinal motility in the postoperative period
Initiation of oral intake in the early postoperative period
Early removal of the patient by reducing postoperative IV fluid infusion
Initiation of early mobilization of the patient in the postoperative period
Reducing opioid use and ensuring pain management
Implement nausea and vomiting prophylaxis
Management of thirsty
Use of recommended non-pharmacological interventions in the management of fear and stress

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative length of hospital stay
Time Frame: From the end of surgery until hospital discharge, up to 10 days
The postoperative length of hospital stay will be calculated in hours. Higher scores indicate delayed discharge. This means a worse outcome.
From the end of surgery until hospital discharge, up to 10 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Complications
Time Frame: up to 30 days after discharge
Postoperative minor and major complications will be recorded.
up to 30 days after discharge
Readmission
Time Frame: up to 30 days after discharge
Readmission to the hospital will be recorded in hours.
up to 30 days after discharge
Postoperative thirst
Time Frame: up to the first oral intake, an average 2 days
Postoperative thirst will be evaluated with Numeric Thirst Scale. Higher scores mean more severe pain, worse outcome.
up to the first oral intake, an average 2 days
Time of first mobilization
Time Frame: up to the first mobilization, an average 12 hours
The first time of postoperative mobilization will be recorded in hours. Higher scores indicate delayed mobilization. This means a worse outcome.
up to the first mobilization, an average 12 hours
Time of first defecation
Time Frame: up to the first defecation, an average 3 days
The first time of postoperative defecation will be recorded in hours. Higher scores indicate delayed defecation. This means a worse outcome.
up to the first defecation, an average 3 days
Postoperative pain
Time Frame: Assessed 5 times on the day of surgery (Postoperative Day 0) after patient awakening, approximately every 4-6 hours
Postoperative pain will be evaluated with Numeric Pain Scale. Higher scores mean more severe pain, worse outcome
Assessed 5 times on the day of surgery (Postoperative Day 0) after patient awakening, approximately every 4-6 hours
Postoperative fear
Time Frame: Assessed 2 times on the day of surgery (Postoperative Day 0) after patient awakening, approximately every 12 hours
Postoperative fear will be evaluated with Children's Fear Scale. Higher scores mean more severe fear, worse outcome.
Assessed 2 times on the day of surgery (Postoperative Day 0) after patient awakening, approximately every 12 hours
Postoperative anxiety
Time Frame: Assessed 2 times on the day of surgery (Postoperative Day 0) after patient awakening, approximately every 12 hours
Postoperative anxiety will be evaluated with Children's State Anxiety. Higher scores mean more severe anxiety, worse outcome.
Assessed 2 times on the day of surgery (Postoperative Day 0) after patient awakening, approximately every 12 hours
Postoperative nausea-vomiting
Time Frame: Assessed 5 times on the day of surgery (Postoperative Day 0) after patient awakening, approximately every 4-6 hours
Postoperative nausea-vomiting will be evaluated with Baxter Retching Faces Scale. Higher scores mean more severe nause, worse outcome
Assessed 5 times on the day of surgery (Postoperative Day 0) after patient awakening, approximately every 4-6 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Buket MERAL, Msc, Karadeniz Technical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2023

Primary Completion (Actual)

May 1, 2024

Study Completion (Actual)

May 31, 2024

Study Registration Dates

First Submitted

June 18, 2023

First Submitted That Met QC Criteria

July 24, 2023

First Posted (Actual)

July 27, 2023

Study Record Updates

Last Update Posted (Estimated)

October 3, 2025

Last Update Submitted That Met QC Criteria

September 30, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

The individual participant data, with identifying information concealed, forming the basis of the results reported in this article, will be made available upon reasonable request to the corresponding author 6-12 months after publication of the article. Researchers should contact the corresponding author to request access to the data.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe